What is Provenge (sipuleucel-T) and what does it treat?
Provenge (sipuleucel-T) is an immunotherapy made from a patient’s own immune cells. It is used to treat men with advanced prostate cancer that is resistant to hormone treatment (castration-resistant) and does not respond to further hormonal therapy [1].
How does Provenge work?
Provenge is prepared by collecting a patient’s immune cells and exposing them ex vivo to a prostate-cancer–related target intended to help activate an immune response. The prepared cells are then given back to the patient to help the immune system fight prostate cancer [1].
Who is it for (and who is it not for)?
Provenge is indicated for men with advanced, hormone-refractory (castration-resistant) prostate cancer [1]. It is not an alternative to treatment for other prostate-cancer settings (such as hormone-sensitive disease) unless specifically supported by the prescribing information.
How is it given and what is the treatment schedule?
Provenge is administered as an infusion and is typically given in a multi-dose regimen rather than a single treatment [1]. The exact schedule depends on the patient’s course and the prescriber’s plan, following the approved instructions.
What outcomes and benefits have been reported?
Clinical studies of Provenge showed improvements in survival for appropriately selected patients with advanced, castration-resistant prostate cancer compared with control regimens [1].
Common side effects patients ask about
Because Provenge is an immune-based therapy, side effects often reflect reactions associated with infusion and immune activation. Reported adverse events can include infusion-related reactions and other treatment-emergent effects typical of immunotherapies [1].
How does Provenge compare with newer prostate cancer immunotherapies?
Provenge was one of the earlier approved immunotherapy options for castration-resistant prostate cancer. Treatment choices today may also include other systemic therapies (including other immunotherapies when appropriate), depending on disease stage and prior treatments. Head-to-head comparisons and sequencing depend on patient factors and evolving clinical evidence.
Is Provenge still available and what does it cost?
Availability and pricing vary by country, payer, and treatment setting. Provenge is a specialized autologous cell therapy, so costs are influenced by manufacturing and administration logistics. For current pricing and coverage decisions, patients typically need to check with their insurer and local pharmacy/oncology center.
Sources
- https://www.provenge.com/what-is-provenge (site providing background on sipuleucel-T and its use in advanced, hormone-refractory prostate cancer)